Soligenix (SNGX) announced that it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte in the treatment of cutaneous T-cell lymphoma, CTCL. The confirmatory Phase 3 study builds on the previous statistically significant Phase 3 study, as well as a recent successful comparative study and an ongoing investigator-initiated study, each further supporting the design of the FLASH2 clinical trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNGX:
- Soligenix announces analysis from protocol HPN-CTCL-04
- Soligenix forms European Medical Advisory Board
- Soligenix initiates Phase 2 clinical trial of SGX945 in Behcet’s Disease
- Soligenix reports Q3 EPS (78c) vs. ($2.56) last year
- Soligenix granted Hong Kong patent for production of synthetic hypericin